CHLD
CHANGE OF OWNER RECEIVED FROM IB
02/12/2026
Back to search
Official data from USPTO
QUANTOOM
Did you know this trademark is already registered in United States?
Before investing in name, identity, and promotion, validate collision risk and registration strategy to avoid wasting time and budget.
Active USPTO registrationType: CombinedOffice: United States
Risk and opportunity diagnosis
Executive reading for naming, filing, and monitoring decisions.
USPTO status
Active USPTO registration
Case type
Application and registration
Recorded events
39
Latest update
02/14/2026
Trademark type
Combined
Nice classes
7, 40, 42
Filing date
08/11/2022
Registration date
08/27/2024
Expiration date
-
Complete case details
Structured fields from the responsible authority and the official record.
Status date
08/27/2024
Last transaction
02/14/2026
Responsible office
United States Patent and Trademark Office
Status code
700
Official register
Principal Register
Drawing code
3
Owner type
98
Owner location
BE
Examiner
BROWN, TINA
Law office
M90
Current location
FILE REPOSITORY (FRANCONIA)
Mark description
The mark consists of the word "QUANTOOM" stylized. The letter "Q" is in upper case and the letters "UANT" and "M" are in lower case. The letters "QUANT" and "M" are in black. The two letters "OO" are replaced by two intertwined squares in two shades of orange. The second square on the right is open and the edges are open towards the direction of letter "M". The color white shown inside the squares represents background and is not claimed as a feature of the mark.
Holders and representatives
Holders
Phoenix Biosciences, société anonyme
Quantoom Biosciences, société anonyme
Representatives
Clifford D Hyra Fresh IP PLC
Technical classification
Nice Classes
Class 7Class 40Class 42
Vienna Codes
No Vienna codes available.
Goods and services
Class 7
Industrial machines for the production of nucleic acids; parts of industrial machines for the production of nucleic acidssingle use trays of reactor tubes
Class 40
Custom manufacturing of biologicscustom manufacturing of biologics using biological organisms in the manufacturing process; custom manufacturing of nucleic acids for clinical trials and for commercial supply by pharmaceutical compounders; custom manufacturing services in the field of biologicspharmaceuticalsbiopharmaceuticalshealth carecell culture and gene therapy and medical productscustom manufacturing of biologicpharmaceuticalsbiopharmaceuticals; treatment of pharmaceutical and chemical products and their components during the custom manufacture of pharmaceuticalsbiopharmaceuticals and nucleic acids; providing advice related to the custom manufacture of pharmaceuticals and materials for clinical trials and for commercial supply; providing information in the field of the custom manufacture of nucleic acids for clinical trials and for commercial supply
Class 42
Scientific research and technological consultancy services in the field of analysis and production of nucleic acids; research and development of nucleic acid generation platforms; scientific research and development applied in particular in the biologicaltechnological and biotechnological fieldsdesign of processesequipmentdisposables and consumables for producing nucleic acids; scientific research and technological development and advice servicescustom designsequencing in the nature of testinganalysis and evaluation and development of nucleic acid generation platforms; engineering services; scientific research and technological consultancy on process development relating to manufacture of nucleic acids; industrial process development for manufacturing of medical preparations; engineering services and scientific research and technological consultancyall on production units for DNA and RNA synthesis; design of tools for the production of biologics; advisory services relating to industrial engineering in the field of manufacturing of biologics; rental of laboratory apparatus and instruments; technological development services in the nature of product developmenttechnology advice and information services in the nature of providing technology information in the field of pharmaceuticals and engineering consultation services in the field of the production of nucleic acids
Publications
History of USPTO decisions and trademark events.
39 publications found
FINO
FINAL DECISION TRANSACTION PROCESSED BY IB
03/01/2025
FICS
FINAL DISPOSITION NOTICE SENT TO IB
02/13/2025
FIMP
FINAL DISPOSITION PROCESSED
02/13/2025
FICR
FINAL DISPOSITION NOTICE CREATED, TO BE SENT TO IB
11/27/2024
NRCC
NOTICE OF REGISTRATION CONFIRMATION EMAILED
08/27/2024
R.PR
REGISTERED-PRINCIPAL REGISTER
08/27/2024
TMBN
TTAB RELEASE CASE TO TRADEMARKS
07/23/2024
ETOP
EXTENSION OF TIME TO OPPOSE PROCESS - TERMINATED
06/02/2024
OPNX
NOTIFICATION OF POSSIBLE OPPOSITION - PROCESSED BY IB
04/08/2024
OPNS
NOTIFICATION OF POSSIBLE OPPOSITION SENT TO IB
03/20/2024
OPNR
NOTIFICATION OF POSSIBLE OPPOSITION CREATED, TO BE SENT TO IB
03/20/2024
ETOF
EXTENSION OF TIME TO OPPOSE RECEIVED
02/19/2024
NPUB
OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED
01/23/2024
PUBO
PUBLISHED FOR OPPOSITION
01/23/2024
GPNX
NOTIFICATION PROCESSED BY IB
01/22/2024
OPNS
NOTIFICATION OF POSSIBLE OPPOSITION SENT TO IB
01/03/2024
OP2R
NOTICE OF START OF OPPOSITION PERIOD CREATED, TO BE SENT TO IB
01/03/2024
NONP
NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED
01/03/2024
TCCA
TEAS CHANGE OF CORRESPONDENCE RECEIVED
12/21/2023
ECDR
TEAS CHANGE OF DOMESTIC REPRESENTATIVES ADDRESS
12/21/2023
ARAA
ATTORNEY/DOM.REP.REVOKED AND/OR APPOINTED
12/21/2023
REAP
TEAS REVOKE/APP/CHANGE ADDR OF ATTY/DOM REP RECEIVED
12/21/2023
CHAN
APPLICANT/CORRESPONDENCE CHANGES (NON-RESPONSIVE) ENTERED
12/21/2023
COAR
TEAS CHANGE OF OWNER ADDRESS RECEIVED
12/21/2023
CNSA
APPROVED FOR PUB - PRINCIPAL REGISTER
12/17/2023
TEME
TEAS/EMAIL CORRESPONDENCE ENTERED
12/15/2023
CRFA
CORRESPONDENCE RECEIVED IN LAW OFFICE
12/14/2023
TROA
TEAS RESPONSE TO OFFICE ACTION RECEIVED
12/14/2023
RFNT
REFUSAL PROCESSED BY IB
08/01/2023
RFCS
NON-FINAL ACTION MAILED - REFUSAL SENT TO IB
07/10/2023
RFRR
REFUSAL PROCESSED BY MPU
07/10/2023
NREP
NEW REPRESENTATIVE AT IB RECEIVED
06/03/2023
RFCR
NON-FINAL ACTION (IB REFUSAL) PREPARED FOR REVIEW
06/03/2023
CNRT
NON-FINAL ACTION WRITTEN
06/02/2023
DOCK
ASSIGNED TO EXAMINER
05/31/2023
MAFR
APPLICATION FILING RECEIPT MAILED
10/25/2022
NWOS
NEW APPLICATION OFFICE SUPPLIED DATA ENTERED
10/21/2022
REPR
SN ASSIGNED FOR SECT 66A APPL FROM IB
10/20/2022
Continuous trademark protection
Get notified about every new filing that threatens QUANTOOM or your mark.
Professional 24-month watch service: we monitor USPTO for you and alert you in time to oppose — before conflicts become losses.